Stocks · News reference

Needham Reiterates Hold on Bausch & Lombto Hold

Sep 15, 2026, 10:07 AMBenzinga Newsdesk

Needham analyst David Saxon reiterates Bausch & Lomb (NYSE:BLCO) from Hold to Hold.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 15, 2026, 1:42 PMBenzinga Newsdesk
Bausch + Lomb Receives FDA Warning Letter Over Sterile Drug Manufacturing At Tampa Plant, Citing Inadequate Aseptic Controls And Persistent Microbial Contamination; Products Deemed Adulterated
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026
BLCO
BenzingaSep 9, 2026, 3:06 PMBenzinga Newsdesk
Leerink Partners Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $24
Leerink Partners analyst Daniel Clark initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $24.
BLCO
Globenewswire IncSep 2, 2026, 5:30 AMNicox Sa
Nicox Announces Extension of Cash Runway
Nicox SA announced an extension of its cash runway to beyond Q1 2028 with €8.4 million in cash as of August 31, 2026. The company expects an FDA approval milestone for NCX 470 by April 30, 2027, which would fund operations into 2029, with subsequent royalties potentially extending visibility further. Management changes include Doug Hubatsch transitioning to Chief Scientific Advisor and Siobhan Garbutt assuming leadership of the development team.
BLCO